Effects of Targeted Suppression of Glutaryl-CoA Dehydrogenase by Lentivirus-Mediated shRNA and Excessive Intake of Lysine on Apoptosis in Rat Striatal Neurons

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Gao, Jinzhi ^a   Zhang, Cai ^a   Fu, Xi ^a   Yi, Qin ^a   Tian, Fengyan ^a   Ning, Qin ^a   Luo, Xiaoping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; GLUTARYL COENZYME A DEHYDROGENASE; LENTIVIRUS VECTOR; LIPOCORTIN 5; LYSINE; SHORT HAIRPIN RNA; TETRAMETHYLRHODAMINE METHYL ESTER; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HYPERMETABOLISM; LENTIVIRINAE; MITOCHONDRIAL MEMBRANE; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; NONHUMAN; RAT; UPREGULATION; WESTERN BLOTTING;

AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BIOLOGICAL TRANSPORT; BRAIN DISEASES, METABOLIC; CASPASE INHIBITORS; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUTARYL-COA DEHYDROGENASE; LENTIVIRUS; LYSINE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOSTRIATUM; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING;

LENTIVIRUS; RATTUS;

EID: 84877050011     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063084     Document Type: Article

References (63)

1. van der Watt G, Owen EP, Berman P, Meldau S, Watermeyer N, et al. (2010) Glutaric aciduria type 1 in South Africa-high incidence of glutaryl-CoA dehydrogenase deficiency in black South Africans. Mol Genet Metab 101: 178-182.
2. Yang L, Yin H, Yang R, Huang X, (2011) Diagnosis, treatment and outcome of glutaric aciduria type 1 in Zhejiang Province, China. Med Sci Monit 17: PH55-59.
3. Kölker S, Christensen E, Leonard JV, Greenberg CR, Boneh A, et al. (2011) Diagnosis and management of glutaric aciduria type I-revised recommendations. J Inherit Metab Dis 34: 677-694.
4. Keyser B, Mühlhausen C, Dickmanns A, Christensen E, Muschol N, et al. (2008) Disease-causing missense mutations affect enzymatic activity, stability and oligomerization of glutaryl-CoA dehydrogenase (GCDH). Hum Mol Genet 17: 3854-3863.
5. Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, et al. (2006) Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 59: 840-847.
6. Kamate M, Patil V, Chetal V, Darak P, Hattiholi V, (2012) Glutaric aciduria type 1: A treatable neurometabolic disorder. Ann Indian Acad Neurol 15: 31-34.
7. Jafari P, Braissant O, Bonafé L, Ballhausen D, (2011) The unsolved puzzle of neuropathogenesis in glutaric aciduria type I. Mol Genet Metab. 104: 425-437.
8. Kölker S, Boy SP, Heringer J, Müller E, Maier EM, et al. (2012) Complementary dietary treatment using lysine-free, arginine-fortified amino acid supplements in glutaric aciduria type 1- A decade of experience. Mol Genet Metab 107: 72-80.
9. Gokmen-Ozel H, Macdonald A, Daly A, Ashmore C, Preece MA, et al. (2012) Dietary practices in glutaric aciduria type 1 over 16 years. J Hum Nutr Diet 25: 514-519.
10. Gerstner B, Gratopp A, Marcinkowski M, Sifringer M, Obladen M, et al. (2005) Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. Pediatr Res 57: 771-776.
11. Latini A, Scussiato K, Leipnitz G, Dutra-Filho CS, Wajner M, (2005) Promotion of oxidative stress by 3-hydroxyglutaric acid in rat striatum. J Inherit Metab Dis 28: 57-67.
12. Leipnitz G, Schumacher C, Scussiato K, Dalcin KB, Wannmacher CM, et al. (2005) Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats. Int J Dev Neurosci 23: 695-701.
13. Olivera-Bravo S, Fernández A, Sarlabós MN, Rosillo JC, Casanova G, et al. (2011) Neonatal astrocyte damage is sufficient to trigger progressive striatal degeneration in a rat model of glutaric acidemia-1. PLoS One 6: e20831.
14. Tian F, Fu X, Gao J, Zhang C, Ning Q, et al. (2012) Caspase-3 mediates apoptosis of striatal cells in GA I rat model. J Huazhong Univ Sci Technolog Med Sci 32: 107-112.
15. Koeller DM, Woontner M, Crnic LS, Kleinschmidt-DeMasters B, Stephens J, et al. (2002) Biochemical, pathologic and behavioral analysis of a mouse model of glutaric acidemia type 1. Hum Mol Genet 11: 347-357.
16. Zinnanti WJ, Lazovic J, Wolpert EB, Antonetti DA, Smith MB, et al. (2006) A diet-induced mouse model for glutaric aciduria type 1. Brain 129: 899-910.
17. Sliva K, Schnierle BS, (2010) Selective gene silencing by viral delivery of short hairpin RNA. Virol J 7: 248.
18. Harper SQ, Gonzalez-Alegre P, (2008) Lentivirus-mediated RNA interference in mammalian neurons. Methods Mol Biol 442: 95-112.
19. D'Costa J, Mansfield SG, Humeau LM, (2009) Lentiviral vectors in clinical trials: Current status. Curr Opin Mol Ther 11: 554-564.
20. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, et al. (2005) Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16: 17-25.
21. Schambach A, Baum C, (2008) Clinical application of lentiviral vectors-concepts and practice. Curr Gene Ther 8: 474-482.
22. Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, et al. (2012) A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria. PLoS One 7: e48644.
23. Ruiz M, Déglon N, (2012) Viral-mediated overexpression of mutant huntingtin to model HD in various species. Neurobiol Dis 48: 202-211.
24. Seredenina T, Gokce O, Luthi-Carter R, (2011) Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS One 6: e22231.
25. Martin E, Betuing S, Pagès C, Cambon K, Auregan G, et al. (2011) Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter. Hum Mol Genet 20: 2422-2434.
26. Lamp J, Keyser B, Koeller DM, Ullrich K, Braulke T, et al. (2011) Glutaric aciduria type 1 metabolites impair the succinate transport from astrocytic to neuronal cells. J Biol Chem 286: 17777-17784.
27. Brewer GJ, Torricelli JR, Evege EK, Price PJ, (1933) Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 35: 567-576.
28. Lin X, Yu Y, Zhao H, Zhang Y, Manela J, et al. (2006) Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 27: 1538-1546.
29. Di Nunzio F, Félix T, Arhel NJ, Nisole S, Charneau P, et al. (2012) HIV-derived vectors for therapy and vaccination against HIV. Vaccine 30: 2499-509.
30. Joshi DC, Bakowska JC (2011) Determination of mitochondrial membrane potential and reactive oxygen species in live rat cortical neurons. J Vis Exp pii: 2704. doi: 10.3791/2704.
31. Floryk D, Houstk J, (1999) Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Biosci Rep 19: 27-34.
32. Christensen E, Ribes A, Merinero B, Zschocke J, (2004) Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27: 861-868.
33. Hedlund GL, Longo N, Pasquali M, (2006) Glutaric acidemia type 1. Am J Med Genet C Semin Med Genet 142C: 86-94.
34. Mühlhausen C, Christensen E, Schwartz M, Muschol N, Ullrich K, et al. (2003) Severe phenotype despite high residual glutaryl-CoA dehydrogenase activity: a novel mutation in a Turkish patient with glutaric aciduria type 1. J Inherit Metab Dis 26: 713-714.
35. Harting I, Neumaier-Probst E, Seitz A, Maier EM, Assmann B, et al. (2009) Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type 1. Brain 132: 1764-1782.
36. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, et al. (2012) Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322: 254-262.
37. Cao Z, LePage KT, Frederick MO, Nicolaou KC, Murray TF, (2010) Involvement of caspase activation in azaspiracid-induced neurotoxicity in neocortical neurons. Toxicol Sci 114: 323-34.
38. Goodman SI, Markey SP, Moe PG, Miles BS, Teng CC, (1975) Glutaric aciduria; a "new" disorder of amino acid metabolism. Biochem Med 12: 12-21.
39. Zafeiriou DI, Zschocke J, Augoustidou-Savvopoulou P, Mauromatis I, Sewell A, et al. (2000) A typical and variable clinical presentation of glutaric aciduria type 1. Neuropediatrics 31: 303-306.
40. Bähr O, Mader I, Zschocke J, Dichgans J, Schulz JB, (2002) Adult onset glutaric aciduria type I presenting with a leukoencephalopathy. Neurology 59: 1802-1804.
41. Frizzo ME, Schwarzbold C, Porciúncula LO, Dalcin KB, Rosa RB, et al. (2004) 3-hydroxyglutaric acid enhances glutamate uptake into astrocytes from cerebral cortex of young rats. Neurochem Int 44: 345-353.
42. Wajner M, Kölker S, Souza DO, Hoffmann GF, de Mello CF, (2004) Modulation of glutamatergic and GABAergic neurotransmission in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27: 825-828.
43. Quincozes-Santos A, Rosa RB, Leipnitz G, de Souza DF, Seminotti B, et al. (2010) Induction of S100B secretion in C6 astroglial cells by the major metabolites accumulating in glutaric acidemia type 1. Metab Brain Dis 25: 191-198.
44. Funk CB, Prasad AN, Frosk P, Sauer S, Kölker S, et al. (2005) Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort. Brain 128: 711-722.
45. Zinnanti WJ, Lazovic J, Housman C, LaNoue K, O'Callaghan JP, et al. (2007) Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type 1. J Clin Invest 117: 3258-3270.
46. Koeller DM, Sauer S, Wajner M, de Mello CF, Goodman SI, et al. (2004) Animal models for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27: 813-818.
47. Sauer SW, Okun JG, Fricker G, Mahringer A, Müller I, et al. (2006) Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. J Neurochem 97: 899-910.
48. Keyser B, Glatzel M, Stellmer F, Kortmann B, Lukacs Z, et al. (2008) Transport and distribution of 3-hydroxyglutaric acid before and during induced encephalopathic crises in a mouse model of glutaric aciduria type 1. Biochim Biophys Acta 1782: 385-390.
49. Sauer SW, Opp S, Mahringer A, Kamiński MM, Thiel C, et al. (2010) Glutaric aciduria type I and methylmalonic aciduria: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus. Biochim Biophys Acta 1802: 552-560.
50. Kölker S, Sauer SW, Okun JG, Hoffmann GF, Koeller DM, (2006) Lysine intake and neurotoxicity in glutaric aciduria type 1: towards a rationale for therapy? Brain 129: e54.
51. Clancy B, Finlay BL, Darlington RB, Anand KJ, (2007) Extrapolating brain development from experimental species to humans. Neurotoxicology 28: 931-937.
52. Bonthuis PJ, Cox KH, Searcy BT, Kumar P, Tobet S, et al. (2010) Of mice and rats: key species variations in the sexual differentiation of brain and behavior. Front Neuroendocrinol 31: 341-358.
53. Iannaccone PM, Jacob HJ, (2009) Rats! Dis Model Mech. 2: 206-210.
54. Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, et al. (2003) Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 64: 1295-1308.
55. Dreyer JL, (2010) Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Methods Mol Biol 614: 3-35.
56. Molles BE, Maskos U, Pons S, Besson M, Guiard P, et al. (2006) Targeted in vivo expression of nicotinic acetylcholine receptors in mouse brain using lentiviral expression vectors. J Mol Neurosci. 30: 105-106.
57. Wajner M, Goodman SI, (2011) Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies. J Bioenerg Biomembr 43: 31-38.
58. Morán M, Moreno-Lastres D, Marín-Buera L, Arenas J, Martín MA, et al. (2012) Mitochondrial respiratory chain dysfunction: Implications in neurodegeneration. Free Radic Biol Med 53: 595-609.
59. Ferreira GC, Tonin A, Schuck PF, Viegas CM, Ceolato PC, et al. (2007) Evidence for a synergistic action of glutaric and 3-hydroxyglutaric acids disturbing rat brain energy metabolism. Int J Dev Neurosci 25: 391-398.
60. Sauer SW, Okun JG, Schwab MA, Crnic LR, Hoffmann GF, et al. (2005) Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency: a role for glutaryl-coenzyme A. J Biol Chem. 280: 21830-21836.
61. Latini A, Rodriguez M, Borba Rosa R, Scussiato K, Leipnitz G, et al. (2005) 3-Hydroxyglutaric acid moderately impairs energy metabolism in brain of young rats. Neuroscience 135: 111-120.
62. Rohn TT, (2010) The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis 15: 1403-1409.
63. Perez-Pinzon MA, Stetler RA, Fiskum G, (2012) Novel mitochondrial targets for neuroprotection. J Cereb Blood Flow Metab 32: 1362-1376.